Advanced search
Publication Cover
Journal of Receptor Research Volume 8, 1988 - Issue 1-4
Journal homepage
12
Views
35
CrossRef citations to date
0
Altmetric
Research Article

Interaction of the D1 Receptor Antagonist Sch 23390 with the Central 5-HT System: Radioligang Binding Studies, Measurements of Biochemical Parameters and Effects on L-5-HTP Syndrome

S. Bischoff Research Department, Pharma. Div., CIBA-GEIGY, Basel, CH, 4002, USA
,
M. Heinrich Research Department, Pharma. Div., CIBA-GEIGY, Basel, CH, 4002, USA
,
J. Krauss Research Department, Pharma. Div., CIBA-GEIGY, Basel, CH, 4002, USA
,
M. A. Sills Drug Discovery Div., CIBA-GEIGY, Summit, NJ, 07901, USA
,
M. Williams Drug Discovery Div., CIBA-GEIGY, Summit, NJ, 07901, USA
&
A. Vassout Research Department, Pharma. Div., CIBA-GEIGY, Basel, CH, 4002, USA
Pages 107-120 | Published online: 26 Sep 2008

References

  • Iorio L. C., Barnett A., Leitz F. M., Houser V. P., Korduba C. A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 1983; 226: 462–468
  • Hicks P. E., Schoemaker H., Langer S. Z. 5-HT receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur. J. Pharmacol. 1984; 105: 339–342
  • Christensen A. V., Arnt J., Hyttel J, Larsen J. J., Svendsen O. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 1984; 34: 1529–1540
  • Markstein R., Hoyer D., Engel G. 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986; 333: 335–341
  • Bischoff S., Heinrich M., Sonntag J.-M., Krauss J. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur. J. Pharmacol. 1986; 129: 367–370
  • Bischoff S., Bittiger H., Krauss J. In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors. Eur. J. Pharmacol 1980; 68: 305–315
  • Bischoff S. Mesohippocampal dopamine system: characterization, functional and clinical implications. The Hippocampus vol. 3, R. L. Isaacson, K. H. Pribram. Plenum Press, New-York 1986; 1–32
  • Leysen J. E., Niemegeers C. J.E., Van Nueten J. M., Laduron P. M. (3H)ketanserin (R41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 1982; 21: 301–314
  • Nelson D. L., Herbet A., Bourgoin S., Glowinski J., Hamon M. Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol. Pharmacol. 1978; 14: 983–995
  • Gozlan H., El Mestikawy S., Pichat L., Glowinski J., Hamon M. Identification of presynaptic autoreceptors using a new ligand: 3H-PAT. Nature 1983; 305: 140–142
  • Hoyer D., Engel G., Kalkman H. O. Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyano-pindolol. Eur. J. Pharmacol. 1985; 118: 1–12
  • Greengrass P., Bremner R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979; 55: 323–326
  • Waldmeier P., Buchle A.-M., Stoecklin K., Fehr B., Feldtrauer J.-J. The effects of amfonelic acid on 5-HT metabolism in rat brain. J. Neural Transm. 1983; 57: 149–165
  • Ortmann R., Bischoff S., Radeke E., Buech O., Delini-Stula A. Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin blockers. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982; 321: 265–270
  • Green A. R., Hall J. E., Rees A. R. A behavioural and biochemical study in rats of 5-hydroxytryptamine agonists and antagonists with observations on structure-activity requirements for agonists. Brit. J. Pharmacol. 1981; 73: 703–719
  • Gunning S. J., Naylor R. J. 5-Hydroxytryptamine can antagonize the ability of metoclopramide and SCH 23390 to enhance electrical field stimulation-evoked contractions of guinea-pig isolated stomach muscle. J. Pharm. Pharmacol. 1985; 37: 78–80
  • Ohlstein E. H., Berkowitz B. A. SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur. J. Pharmacol. 1985; 108: 205–208
  • Christensen A. V., Arnt J., Hyttel J., Svendsen O. Behavioural correlates to the dopamine D-1 and D-2 antagonists. Pol. J. Pharmacol. Pharm. 1984; 36: 249–264
  • Andersen P., Nielsen E. B. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo. Acta pharmacol. et toxicol. 1986; 59: 315–318

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.